PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Relugolix with estradiol and norethisterone acetate - Endometriosis

PAD Profile : Relugolix with estradiol and norethisterone acetate - Endometriosis

Brand Names Include :
Ryeqo

Traffic Light Status

Status 1 of 1.

Status :
N/A
Important
Formulations :
  • Tablets
Important Information :
Not assessed for formulary status. An application to APC is required.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD2
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

No drugs returned.

Other Indications

Additional Documents

No additional documents returned.

Committee Recommendations

Date
Committee Name
Narrative
02 October 2024
Not Set

This drug has not yet been assessed for formulary status for endometriosis and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.

Before prescribing this drug it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

Associated BNF Codes

06. Endocrine System
06.07.02. Drugs affecting gonadotrophins
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More